| Protocol ID | NCT00571740 |
| Registration Date | 2007-12-12 |
| Status | Withdrawn |
| Sponsor | Alliance for Clinical Trials in Oncology |
| Country | – |
| Industry | not industry |
| Blinding | unblinded |
| Center Type | – |
| Scope | – |
| First Patient In | – |
| Last Patient Out | – |
| Publication | n |
| Gender % | ALL |
| Mean Age | 18 Years - |
NCT00571740
Randomized Phase II Trial of Cetuximab/Bevacizumab (CB) as Palliative First-Line Therapy in Patients With Advanced Colorectal Cancer Followed by FOLFOX+CB vs. FOLFOX+B
| Field |
OPENAI
gpt-4o 4408ms / 9665 tok |
GLM
glm-5.1 7962ms / 9860 tok |
CLAUDE
claude-sonnet-4-20250514 7662ms / 11323 tok |
Review |
|---|---|---|---|---|
| rct_type | parallel RCT | parallel RCT | parallel RCT | OK |
| cancer_status | Cancer | Cancer | Cancer | OK |
| non_cancer_spec | N/A | N/A | N/A | OK |
| setting_patient | outpatient | outpatient | outpatient | OK |
| setting_place |
other
hospital → other
shaky reasoning✓ Unanimous
Initial: hospital
Requery: other — The trial is a multicenter study with treatments involving intravenous administration of drugs, likely in outpatient or community settings, but not requiring hospital admission.
|
other
other
shaky reasoning✓ Unanimous
Initial: other
|
other
other → other
shaky reasoning✓ Unanimous
Initial: other
Requery: other — The study involves IV infusion treatments (bevacizumab, cetuximab, FOLFOX chemotherapy) that are typically administered in outpatient oncology clinics or infusion centers, not requiring hospitalization.
|
OK |
| feasibility | fully powered RCT | fully powered RCT | fully powered RCT | OK |
| intervention_pharmacologic | yes | yes | yes | OK |
| intervention_chemo_immuno_radio | yes | yes | yes | OK |
| intervention_complementary | no | no | no | OK |
| intervention_device | no | no | no | OK |
| intervention_psychological | no | no | no | OK |
| intervention_complex | no | no | no | OK |
| intervention_acp | no | no | no | OK |
| intervention_music | no | no | no | OK |
| intervention_screening | no | no | no | OK |
| intervention_palliative | no | no | no | OK |
| intervention_education | no | no | no | OK |
| intervention_digital | no | no | no | OK |
| intervention_other | no | no | no | OK |
| outcome_symptom |
no
no → no
shaky reasoning✓ Unanimous
Initial: no
Requery: no — The clinical trial does not list any symptom measures as primary or secondary outcomes using validated instruments or direct symptom assessment.
|
no
yes → no
shaky reasoning✓ Unanimous
Initial: yes
Requery: no — The study measures quality of life using the UNISCALE, Skindex-16, and Skin Assessment Questionnaires, but does not use specific validated symptom instruments like ESAS, MSAS, or scales for pain, nausea, or fatigue.
|
no
no → no
shaky reasoning✓ Unanimous
Initial: no
Requery: no — The trial measures quality of life using UNISCALE and Skindex-16 questionnaires rather than specific symptom assessment instruments, and focuses on oncological endpoints like progression-free survival and tumor response.
|
OK |
| outcome_qol | yes | yes | yes | OK |
| outcome_dignity | no | no | no | OK |
| outcome_cost | yes | yes | yes | OK |
| outcome_other | yes | yes | yes | OK |
| pharmacologic_sub |
immunotherapy
off label use → immunotherapy
shaky reasoning✓ Unanimous
Initial: off label use
Requery: immunotherapy — Cetuximab and bevacizumab are monoclonal antibodies used in cancer treatment, classifying them under immunotherapy.
|
immunotherapy
chemotherapy → immunotherapy
shaky reasoning✓ Unanimous
Initial: chemotherapy
Requery: immunotherapy — The trial utilizes monoclonal antibodies (cetuximab and bevacizumab) for cancer treatment, which falls under the immunotherapy category.
|
immunotherapy
chemotherapy → immunotherapy
shaky reasoning✓ Unanimous
Initial: chemotherapy
Requery: immunotherapy — This trial uses monoclonal antibodies (cetuximab and bevacizumab) for cancer treatment, which are classified as immunotherapy interventions.
|
OK |